Katherine M Owsiany1,2, Rebecca A Deaton2, Karen G Soohoo3, Anh Tram Nguyen4, Gary K Owens2. 1. University of Virginia School of Medicine, Charlottesville (K.M.O.). 2. Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville (K.M.O., R.A.D., G.K.O.). 3. Eastern Virginia Medical School, Norfolk (K.G.S.). 4. Duke University School of Medicine, Durham, NC (A.T.N.).
Abstract
BACKGROUND: Smooth muscle cells (SMCs) in atherosclerotic plaque take on multiple nonclassical phenotypes that may affect plaque stability and, therefore, the likelihood of myocardial infarction or stroke. However, the mechanisms by which these cells affect stability are only beginning to be explored. METHODS: In this study, we investigated the contribution of inflammatory MCP1 (monocyte chemoattractant protein 1) produced by both classical Myh11 (myosin heavy chain 11)+ SMCs and SMCs that have transitioned through an Lgals3 (galectin 3)+ state in atherosclerosis using smooth muscle lineage tracing mice that label all Myh11+ cells and a dual lineage tracing system that targets Lgals3-transitioned SMC only. RESULTS: We show that loss of MCP1 in all Myh11+ smooth muscle results in a paradoxical increase in plaque size and macrophage content, driven by a baseline systemic monocytosis early in atherosclerosis pathogenesis. In contrast, knockout of MCP1 in Lgals3-transitioned SMCs using a complex dual lineage tracing system resulted in lesions with an increased Acta2 (actin alpha 2, smooth muscle)+ fibrous cap and decreased investment of Lgals3-transitioned SMCs, consistent with increased plaque stability. Finally, using flow cytometry and single-cell RNA sequencing, we show that MCP1 produced by Lgals3-transitioned SMCs influences multiple populations of inflammatory cells in late-stage plaques. CONCLUSIONS: MCP1 produced by classical SMCs influences monocyte levels beginning early in disease and was atheroprotective, while MCP1 produced by the Lgals3-transitioned subset of SMCs exacerbated plaque pathogenesis in late-stage disease. Results are the first to determine the function of Lgals3-transitioned inflammatory SMCs in atherosclerosis and highlight the need for caution when considering therapeutic interventions involving MCP1.
BACKGROUND: Smooth muscle cells (SMCs) in atherosclerotic plaque take on multiple nonclassical phenotypes that may affect plaque stability and, therefore, the likelihood of myocardial infarction or stroke. However, the mechanisms by which these cells affect stability are only beginning to be explored. METHODS: In this study, we investigated the contribution of inflammatory MCP1 (monocyte chemoattractant protein 1) produced by both classical Myh11 (myosin heavy chain 11)+ SMCs and SMCs that have transitioned through an Lgals3 (galectin 3)+ state in atherosclerosis using smooth muscle lineage tracing mice that label all Myh11+ cells and a dual lineage tracing system that targets Lgals3-transitioned SMC only. RESULTS: We show that loss of MCP1 in all Myh11+ smooth muscle results in a paradoxical increase in plaque size and macrophage content, driven by a baseline systemic monocytosis early in atherosclerosis pathogenesis. In contrast, knockout of MCP1 in Lgals3-transitioned SMCs using a complex dual lineage tracing system resulted in lesions with an increased Acta2 (actin alpha 2, smooth muscle)+ fibrous cap and decreased investment of Lgals3-transitioned SMCs, consistent with increased plaque stability. Finally, using flow cytometry and single-cell RNA sequencing, we show that MCP1 produced by Lgals3-transitioned SMCs influences multiple populations of inflammatory cells in late-stage plaques. CONCLUSIONS: MCP1 produced by classical SMCs influences monocyte levels beginning early in disease and was atheroprotective, while MCP1 produced by the Lgals3-transitioned subset of SMCs exacerbated plaque pathogenesis in late-stage disease. Results are the first to determine the function of Lgals3-transitioned inflammatory SMCs in atherosclerosis and highlight the need for caution when considering therapeutic interventions involving MCP1.
Authors: Jian Guo; Vivian de Waard; Miranda Van Eck; Reeni B Hildebrand; Eva J A van Wanrooij; Johan Kuiper; Nobuyo Maeda; G Martin Benson; Pieter H E Groot; Theo J C Van Berkel Journal: Arterioscler Thromb Vasc Biol Date: 2005-03-17 Impact factor: 8.311
Authors: Brittany G Durgin; Olga A Cherepanova; Delphine Gomez; Themistoclis Karaoli; Gabriel F Alencar; Joshua T Butcher; Yu-Qing Zhou; Michelle P Bendeck; Brant E Isakson; Gary K Owens; Jessica J Connelly Journal: Am J Physiol Heart Circ Physiol Date: 2017-03-10 Impact factor: 4.733
Authors: Sima Allahverdian; Ali Cyrus Chehroudi; Bruce M McManus; Thomas Abraham; Gordon A Francis Journal: Circulation Date: 2014-01-30 Impact factor: 29.690
Authors: X Yu; S Dluz; D T Graves; L Zhang; H N Antoniades; W Hollander; S Prusty; A J Valente; C J Schwartz; G E Sonenshein Journal: Proc Natl Acad Sci U S A Date: 1992-08-01 Impact factor: 11.205
Authors: Ilze Bot; Natalia V Ortiz Zacarías; Wilhelmus E A de Witte; Henk de Vries; Peter J van Santbrink; Daniël van der Velden; Mara J Kröner; Dirk-Jan van der Berg; Dean Stamos; Elizabeth C M de Lange; Johan Kuiper; Adriaan P IJzerman; Laura H Heitman Journal: Sci Rep Date: 2017-03-03 Impact factor: 4.379
Authors: Matthew L Neal; Alexa M Boyle; Kevin M Budge; Fayez F Safadi; Jason R Richardson Journal: J Neuroinflammation Date: 2018-03-08 Impact factor: 8.322